We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Medical's (VAR) ProBeam Platform Gains Foothold in UK
Read MoreHide Full Article
Varian Medical Systems recently installed a Varian ProBeam cyclotron at University College Hospitals London NHS Foundation Trust’s (“UCLH”) proton beam therapy center. Notably, cyclotron is a particle accelerator which accelerates protons to two thirds the speed of light for clinical use. UCLH will feature four treatment rooms and will commence treating patients from 2020.
Earlier, in 2017, Varian Medical delivered a cyclotron to the U.K.'s first National Health Service high energy proton therapy center.
With this latest move, the California-based provider of cancer care will further consolidate its global foothold in providing proton therapy solutions.
We believe such positive developments will further boost Varian’s shares, which have gained 10.4% against the industry’s decline of 4.4% in the past six months.
Market Prospects
Per Grand View Research, the global proton therapy systems market is expected to reach $2.88 billion by 2025. Increasing numbers of proton therapy centers, rising prevalence of cancer and hospitals’ focus on investment are believed to be the primary growth drivers.
Varian - The Proton Therapy Magnate
Varian Medical's ProBeam system is at the forefront of the industry, having created the world's first commercially available pencil beam scanning system. Notably, it is the first of its kind to deliver intensity-modulated proton therapy.
Per management, since fiscal 2017, Varian Medical’s sales pipeline has remained solid with six proton orders. The company has also been focusing on education and training for the continued growth of proton therapy around the world.
Recently, Varian Medical and the University of Maryland School of Medicine reached their first educational milestone at the Maryland Proton Treatment Center. More than 150 medical professionals have been trained in this joint venture.
Furthermore, recently St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute successfully completed its first pediatric patient treatment with the Varian ProBeam proton therapy system. (Read More: Varian Medical's ProBeam Platform Gains Traction in Russia).
Earlier, Varian Medical’s ProBeam was also selected by Penn Medicine, an academic medical center of the University of Pennsylvania. Additionally, the company’s coveted ARIA information management system and Eclipse treatment planning system were also picked by Penn Medicine.
Zacks Rank & Other Stocks to Consider
Varian Medical currently flaunts a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Genomic Health , Abiomed and Stryker Corporation (SYK - Free Report) .
Abiomed has a projected long-term earnings growth rate of 27%. The stock sports a Zacks Rank #1.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Varian Medical's (VAR) ProBeam Platform Gains Foothold in UK
Varian Medical Systems recently installed a Varian ProBeam cyclotron at University College Hospitals London NHS Foundation Trust’s (“UCLH”) proton beam therapy center. Notably, cyclotron is a particle accelerator which accelerates protons to two thirds the speed of light for clinical use. UCLH will feature four treatment rooms and will commence treating patients from 2020.
Earlier, in 2017, Varian Medical delivered a cyclotron to the U.K.'s first National Health Service high energy proton therapy center.
With this latest move, the California-based provider of cancer care will further consolidate its global foothold in providing proton therapy solutions.
We believe such positive developments will further boost Varian’s shares, which have gained 10.4% against the industry’s decline of 4.4% in the past six months.
Market Prospects
Per Grand View Research, the global proton therapy systems market is expected to reach $2.88 billion by 2025. Increasing numbers of proton therapy centers, rising prevalence of cancer and hospitals’ focus on investment are believed to be the primary growth drivers.
Varian - The Proton Therapy Magnate
Varian Medical's ProBeam system is at the forefront of the industry, having created the world's first commercially available pencil beam scanning system. Notably, it is the first of its kind to deliver intensity-modulated proton therapy.
Per management, since fiscal 2017, Varian Medical’s sales pipeline has remained solid with six proton orders. The company has also been focusing on education and training for the continued growth of proton therapy around the world.
Recently, Varian Medical and the University of Maryland School of Medicine reached their first educational milestone at the Maryland Proton Treatment Center. More than 150 medical professionals have been trained in this joint venture.
Furthermore, recently St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute successfully completed its first pediatric patient treatment with the Varian ProBeam proton therapy system. (Read More: Varian Medical's ProBeam Platform Gains Traction in Russia).
Earlier, Varian Medical’s ProBeam was also selected by Penn Medicine, an academic medical center of the University of Pennsylvania. Additionally, the company’s coveted ARIA information management system and Eclipse treatment planning system were also picked by Penn Medicine.
Zacks Rank & Other Stocks to Consider
Varian Medical currently flaunts a Zacks Rank #1 (Strong Buy).
A few other top-ranked stocks in the broader medical space are Genomic Health , Abiomed and Stryker Corporation (SYK - Free Report) .
Genomic Health has an expected earnings growth rate of 187.5% for the current quarter. The stock sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abiomed has a projected long-term earnings growth rate of 27%. The stock sports a Zacks Rank #1.
Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2 (Buy).
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>